Clinical trial • Phase I • Oncology
AUTX-703 for Acute myeloid leukaemia (relapsed/refractory) | Myelodysplastic syndrome (relapsed/refractory)
Phase I trial of AUTX-703 for Acute myeloid leukaemia (relapsed/refractory) | Myelodysplastic syndrome (relapsed/refractory). 59 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Acute myeloid leukaemia (relapsed/refractory) | Myelodysplastic syndrome (relapsed/refractory)
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 23-10-2025
- First CTIS Authorization Date
- 04-02-2026
Trial design
Phase I trial across 2 sites in France.
- Target Sample Size
- 59
Recruitment
- Planned Sample Size
- 59
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 59
France
- Earliest CTIS Part Ii Submission Date
- 19-12-2025
- Latest Decision Or Authorization Date
- 04-02-2026
- Processing Time Days
- 47
- Number Of Sites
- 2
- Number Of Participants
- 10
Sites
- Site Name
- Institut Gustave Roussy
- Contact Person Name
- Christophe Willekens
- Contact Person Email
- christophe.willekens@gustaveroussy.fr
- Site Name
- Oncopole Claudius Regaud
- Contact Person Name
- Christian RECHER
- Contact Person Email
- recher.christian@iuct-oncopole.fr
Sponsor
Primary sponsor
- Full Name
- Auron Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- AUTX-703
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)